Teva Pharmaceutical Industries Ltd to Post Q1 2019 Earnings of $0.73 Per Share, Oppenheimer Forecasts (TEVA)

Share on StockTwits

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Analysts at Oppenheimer reduced their Q1 2019 earnings estimates for shares of Teva Pharmaceutical Industries in a research note issued to investors on Sunday, February 10th. Oppenheimer analyst E. Rajavelu now forecasts that the company will earn $0.73 per share for the quarter, down from their prior estimate of $0.75. Oppenheimer has a “Hold” rating on the stock. Oppenheimer also issued estimates for Teva Pharmaceutical Industries’ Q2 2019 earnings at $0.60 EPS.

A number of other equities analysts have also recently commented on the stock. UBS Group raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating in a research note on Wednesday, January 23rd. Bank of America raised shares of Teva Pharmaceutical Industries from an “underperform” rating to a “buy” rating and set a $16.12 price target for the company in a research note on Thursday, January 3rd. Piper Jaffray Companies raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and boosted their price target for the stock from $15.00 to $16.00 in a research note on Wednesday, January 23rd. Morgan Stanley raised shares of Teva Pharmaceutical Industries from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $20.00 to $27.00 in a research note on Monday, November 5th. Finally, Zacks Investment Research cut shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research note on Monday, January 21st. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries has a consensus rating of “Hold” and an average price target of $22.98.

TEVA stock opened at $17.63 on Tuesday. The company has a debt-to-equity ratio of 1.75, a current ratio of 0.94 and a quick ratio of 0.61. Teva Pharmaceutical Industries has a one year low of $14.59 and a one year high of $25.96. The company has a market capitalization of $19.44 billion, a price-to-earnings ratio of 4.49, a P/E/G ratio of 5.83 and a beta of 1.46.

In other news, VP Hafrun Fridriksdottir sold 1,643 shares of the company’s stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $15.70, for a total value of $25,795.10. Following the completion of the sale, the vice president now owns 13,469 shares of the company’s stock, valued at approximately $211,463.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.43% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the company. Bruderman Asset Management LLC boosted its position in Teva Pharmaceutical Industries by 2,175.0% during the 4th quarter. Bruderman Asset Management LLC now owns 2,366 shares of the company’s stock valued at $36,000 after buying an additional 2,262 shares during the period. Rational Advisors LLC purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at $49,000. Capital Investment Advisory Services LLC purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at $56,000. Quadrant Capital Group LLC boosted its position in Teva Pharmaceutical Industries by 420.3% during the 4th quarter. Quadrant Capital Group LLC now owns 5,541 shares of the company’s stock valued at $80,000 after buying an additional 4,476 shares during the period. Finally, Whittier Trust Co. boosted its position in Teva Pharmaceutical Industries by 35.4% during the 4th quarter. Whittier Trust Co. now owns 5,481 shares of the company’s stock valued at $84,000 after buying an additional 1,434 shares during the period. 62.11% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: Bond

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.